Markets:

Overview

News

Currencies

International

Treasuries

Simulations Plus, Inc. - Common Stock (NQ:SLP)

14.65 +0.18 (+1.24%)

Streaming Delayed Price Updated: 10:30 AM EDT, May 21, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Simulations Plus, Inc. - Common Stock

< Previous 1 2

...

5 6 7 8 9 10 11 12 Next >

Researchers Use the Simulations Plus DILIsym® Platform to Predict Safety of Combined CBD and VPA Treatment

August 15, 2023

From Simulations Plus, Inc.

Via Business Wire

Simulations Plus Releases ADMET Predictor® 11

July 13, 2023

From Simulations Plus, Inc.

Via Business Wire

Recap: Simulations Plus Q3 Earnings ↗

July 06, 2023

Via Benzinga

Simulations Plus's Earnings: A Preview ↗

July 05, 2023

Via Benzinga

Preview: Simulations Plus's Earnings ↗

April 04, 2023

Via Benzinga

Simulations An Attractive Vehicle For Investors Seeking Exposure To Biotech Innovation Themes, Analyst Says ↗

July 07, 2023

Oppenheimer analyst Francois Brisebois reiterated an Outperform rating on Simulations Plus, Inc. (NASDAQ: SLP) with a

Via Benzinga

Costco, AZZ And 3 Stocks To Watch Heading Into Friday ↗

July 07, 2023

With U.S. stock futures trading slightly lower this morning on Friday, some of the stocks that may grab investor focus today are as follows:

Via Benzinga

Simulations Plus Reports Third Quarter Fiscal 2023 Financial Results

July 06, 2023

From Simulations Plus, Inc.

Via Business Wire

Simulations Plus Announces Third Quarter Fiscal Year 2023 Earnings and Conference Call Date

June 21, 2023

From Simulations Plus, Inc.

Via Business Wire

Simulations Plus Is High-Growth Investment Opportunity In The Wake Of Immunetrics Acquisition: Analyst ↗

June 21, 2023

Oppenheimer analyst Francois Brisebois reiterated an Outperform rating on the shares of Simulations Plus, Inc. (NASDAQ: SLP),

Via Benzinga

Simulations Plus Acquires Immunetrics to Expand its Immunology and Oncology Drug Development Capabilities

June 20, 2023

From Simulations Plus, Inc.

Via Business Wire

7 Stocks Under $50 to Buy (and Never Sell) ↗

May 29, 2023

Although you usually get what you pay for, these best affordable stocks to invest in punch above their weight class.

Via InvestorPlace

Simulations Plus Launches New Integrated Pulmonary Software and Services Package to Streamline Drug Development and Improve Patient Outcomes

May 10, 2023

From Simulations Plus, Inc.

Via Business Wire

Benzinga's Top Ratings Upgrades, Downgrades For May 9, 2023 ↗

May 09, 2023

Via Benzinga

Roblox And 3 Other Stocks Insiders Are Selling ↗

April 28, 2023

The Nasdaq Composite closed sharply higher on Thursday. Investors, meanwhile, focused on some notable insider trades.

Via Benzinga

Simulations Plus Receives U.S. FDA Renewal for DILIsym Software Licenses

April 18, 2023

From Simulations Plus, Inc.

Via Business Wire

Simulations Plus Reports Second Quarter Fiscal 2023 Financial Results

April 05, 2023

From Simulations Plus, Inc.

Via Business Wire

MIDD+ 2023 Panelists Discuss How to Increase Gender Equity for Women in Science

March 30, 2023

From Simulations Plus, Inc.

Via Business Wire

Simulations Plus Sets Date for Second Quarter Fiscal Year 2023 Earnings Release and Conference Call

March 21, 2023

From Simulations Plus, Inc.

Via Business Wire

Simulations Plus to Present at Sidoti March Small-Cap Conference

March 16, 2023

From Simulations Plus, Inc.

Via Business Wire

Simulations Plus Enters New Strategic Collaboration to Discover Anticancer Therapies Through Its AI-Driven Drug Design Technology

March 28, 2023

From Simulations Plus, Inc.

Via Business Wire

Simulations Plus Enters Partnership to Apply AI/ML Technologies to Design Novel Compounds

March 15, 2023

From Simulations Plus, Inc.

Via Business Wire

Lixoft Adds New Data Formatting and Reporting Modules to MonolixSuite™ in Version 2023R1

March 09, 2023

From Simulations Plus, Inc.

Via Business Wire

Simulations Plus to Present at Oppenheimer 33rd Annual Healthcare Conference

March 07, 2023

From Simulations Plus, Inc.

Via Business Wire

Simulations Plus to Present at Raymond James 44th Annual Institutional Investors Conference

February 28, 2023

From Simulations Plus, Inc.

Via Business Wire

Simulations Plus and Global Agrochemicals Leader to Collaborate on Machine Learning Models

February 16, 2023

From Simulations Plus, Inc.

Via Business Wire

Simulations Plus Releases Redesigned NAFLDsym® QSP Software Tool

February 09, 2023

From Simulations Plus, Inc.

Via Business Wire

Simulations Plus Releases DILIsym X (DSX) Beta with Redesigned Software Infrastructure

January 12, 2023

From Simulations Plus, Inc.

Via Business Wire

Simulations Plus Executes $20 Million Accelerated Share Repurchase Agreement

January 11, 2023

From Simulations Plus, Inc.

Via Business Wire

Why ABVC BioPharma Shares Are Trading Higher By 129%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗

January 05, 2023

Gainers Bellerophon Therapeutics, Inc. (NASDAQ: BLPH) shares surged 179.3% to $2.4585 after the company announced that it has entered into a license agreement for the development and commercialization...

Via Benzinga

< Previous 1 2

...

5 6 7 8 9 10 11 12 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.